Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Elena A DmitrievaEugene A NikitinAnastasia A IgnatovaVladimir I VorobyevAleksandr V PoletaevElena A SereginaKirill A VoroninDmitrii M PolokhovAleksey A MaschanGalina A NovichkovaMikhail A PanteleevVadim V PtushkinPublished in: Journal of thrombosis and haemostasis : JTH (2021)
Our results suggest that ibrutinib-dependent bleeding in CLL patients involves three mechanisms: decreased platelet count (the most important discriminator between bleeding and non-bleeding patients), impaired platelet response to ADP caused by CLL, and inhibition by ibrutinib. Initially, ibrutinib shifts the balance to bleeding, but then it is restored because of the improved response to ADP.